Stratsemble
Preparation · Stage 2 of 5 — Test
ABT · Abbott LaboratoriesStocks

Does the Money Flow Index strategy beat buy & hold on Abbott Laboratories? (ABT · backtested honestly)

The Money Flow Index is a volume-weighted RSI: it weights each day's typical price by volume, then gauges how stretched buying pressure is versus selling on a 0-100 scale.

Lagged buy & hold2021-10-07 → 2026-10-06 · 1,254 barsCosts & slippage onvs Buy & HoldHypothetical · not advice
Total return
-17.1%
Buy & hold -8.2%
vs Buy & Hold
-8.8 pts
lagged the benchmark
Max drawdown
-38.8%
Sharpe -0.15 · 5 trades
The honest read

Over this period, Money Flow Index on Abbott Laboratories returned -17.1%, while simply buying and holding returned -8.2% — it lagged buy & hold by 8.8 points, with a worst drawdown of -38.8%. It traded 5 times and sat in cash about 61% of the time. It's a mechanism you test — not a recommendation.

What this settles — and the next dig

It lagged buy & hold over this window — that's a result, and a backtest you can kill for free just did its job. Re-tuning this same idea until it looks better only adds another shot at looking good by luck, so the honest next move is a fresh one: test a different strategy on Abbott Laboratories, or build your own — free. Most ideas die cheaply right here, and that's exactly how the rare one that holds up gets found.

Or stop here — walking away from an idea that didn't beat simply holding is a result, not a failure.

Interactive

Run it yourself

Change the parameters and the window, then re-run — no account needed.

Change the rules? Open the Money Flow Index rules on Abbott Laboratories in the no-code builder — the same rules tested here — and make them your own.

Open in the builder →
Worked example

Two real trades from this backtest

Shown at the modeled fills — entries at the next open, protective stops and targets at their level; costs on. A single trade is never a signal and says nothing about the next one — not the best or worst, a middling winner and a middling loser among the completed trades.

5 trades total — 2 winners, 3 losers (40% won). Below is one of each, not a scoreboard.

  1. Entry. A long entry fired; filled at the next open on 2025-08-29 at $132.01 — never the signal bar's own close.
  2. Held. 122 daily bars.
  3. Exit. Exited on 2026-02-25 at $114.91 (the exit rule fired (filled at the next open)).
  4. Result. -13.05% after costs.

The worst single trade in this whole test reached -14.86%.

  1. Entry. A long entry fired; filled at the next open on 2026-03-23 at $107.07 — never the signal bar's own close.
  2. Held. 97 daily bars.
  3. Exit. Exited on 2026-08-11 at $108.62 (the exit rule fired (filled at the next open)).
  4. Result. +1.35% after costs.

Trading costs + slippage (0.10%) are already deducted from every figure above. One trade is never the edge — it's the whole distribution (the win rate, the losers, the reality-check) that matters; this just makes the mechanics concrete. It describes the past; it is not a prediction.

Put this honest verdict on your site

A live badge that re-runs itself and links back here. Free to embed on any blog, newsletter or forum — it shows the honest result, beat or lagged.

<iframe src="https://stratsemble.com/embed/abbott-mfi-backtest" width="360" height="340" style="border:0;border-radius:12px;max-width:100%" loading="lazy" title="Does the Money Flow Index strategy beat buy & hold on Abbott Laboratories?"></iframe>
How to read this
  • • The strategy line is Money Flow Index on Abbott Laboratories; the dashed line is simply buying and holding ABT. Beating the dashed line is the whole point — many strategies don't.
  • • Max drawdown is the worst peak-to-trough fall you'd have sat through. A higher return with a much deeper drawdown is not obviously better.
  • • Every fill assumes next-open execution with costs & slippage on — no acting on prices you couldn't have known.
  • • A small number of trades means a small sample. Treat a great-looking result on a handful of trades with suspicion.
What this is — and isn't

This is a hypothetical backtest of a well-known mechanism on past data. It is not advice, not a prediction, and not a claim that the strategy works. I hold no funds and place no orders. The value here is the ability to test an idea honestly — see where it would have helped, and where it would have hurt — before you ever risk real money on your own broker.

How this is computed → · who's behind it · where a backtest fits

See what actually beats buy & hold — most don't, here are the rare few that do →